Online citations, reference lists, and bibliographies.
← Back to Search

Clinical And Pharmacokinetic Phase I Study Of Multitargeted Antifolate (LY231514) In Combination With Cisplatin.

R. Thödtmann, H. Depenbrock, H. Dumez, J. Blatter, R. D. Johnson, A. V. Van Oosterom, A. Hanauske
Published 1999 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
PURPOSE Multitargeted antifolate (MTA; LY231514) has broad preclinical antitumor activity and inhibits a variety of intracellular enzymes involved in the folate pathways. This study was designed to (1) determine the maximum-tolerated dose (MTD), dose-limiting toxicities (DLT), and pharmacokinetics of MTA combined with cisplatin; (2) determine a recommended dose for phase II studies; and (3) collect anecdotal information on the antitumor activity of MTA combined with cisplatin. PATIENTS AND METHODS Patients with solid tumors received MTA intravenously over 10 minutes and cisplatin over 2 hours once every 21 days. In cohort 1, both agents were administered on day 1 starting with MTA 300 mg/m(2) and cisplatin 60 mg/m(2). In cohort 2, MTA (500 or 600 mg/m(2)) was administered on day 1, followed by cisplatin (75 mg/m(2)) on day 2. RESULTS In cohort 1, 40 assessable patients received 159 courses of treatment. The MTD was MTA 600 mg/m(2)/cisplatin 100 mg/m(2). DLTs were reversible leukopenia/neutropenia and delayed fatigue. Hydration before cisplatin therapy did not influence MTA pharmacokinetics. Eleven objective remissions included one complete response in a patient with relapsed squamous cell head and neck carcinoma, and partial responses in four of ten patients with epithelial pleural mesothelioma. In cohort 2, 11 assessable patients received 23 courses of treatment. The MTD was MTA 600 mg/m(2) and cisplatin 75 mg/m(2). DLTs were neutropenic sepsis, diarrhea, and skin toxicity. Two patients died of treatment-related complications during the study. Two patients had objective remissions (one mesothelioma patient, one colon cancer patient). CONCLUSION The combination of MTA and cisplatin is clinically active, and administering both agents on day 1 is superior to a split schedule. Further development of this combination for mesothelioma is warranted.
This paper references

This paper is referenced by
Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B.
H. Kindler (2001)
Platinum and Pemetrexed Combination in Advanced Solid Tumors
Giovanna Finocchiaro (2010)
The evolving role of gemcitabine and pemetrexed (Alimta) in the management of patients with malignant mesothelioma.
M. Green (2002)
Three emerging new drugs for NSCLC: pemetrexed, bortezomib, and cetuximab.
S. Dubey (2005)
Pemetrexed, A Modulator of AMP-activated Kinase Signaling and an Inhibitor of Wild type and Mutant p53
Stuti Agarwal (2015)
Preclinical and Early Clinical Development of Chemotherapeutic Drugs, Mechanism‐Based Agents and Biologics
A. Hanauske (2017)
Fibrous tumors of the pleura
M. Perrot (2000)
Commentary (Vogelzang/Manno): Update on Malignant Mesothelioma
N. Vogelzang (2005)
Novel drugs in development for malignant mesothelioma.
K. Maung (2002)
Phase I II S tudy o f P emetrexed i n C ombination W ith C isplatin Versus C isplatin A lone i n P atients W ith M alignant P leural Mesothelioma
N. Vogelzang (2003)
mesothelioma conformal radiation with or without chemotherapy for malignant pleural Radical pleurectomy/decortication and intraoperative radiotherapy followed by
David Mark Jablons (2013)
Overview of phase I/II pemetrexed studies.
A. Hanauske (2004)
Pemetrexed for diffuse malignant pleural mesothelioma.
C. Manegold (2002)
Docetaxel for malignant mesothelioma: phase II study of the Eastern Cooperative Oncology Group.
C. Belani (2004)
Tumors of the Pleura and Mediastinum
M. Sovak (2008)
Treatment of Non-Small Cell Lung Cancer: Focus on Pemetrexed Disodium
Josephine Louella Feliciano (2010)
Recent Advances in the Treatment of Malignant Pleural Mesothelioma
S. Ramalingam (2008)
The emerging role of antifolates in the treatment of malignant pleural mesothelioma.
K. Fizazi (2002)
Multimodality therapy in mesothelioma: role of chemotherapy.
N. Vogelzang (2004)
A phase II evaluation of pemetrexed (Alimta, LY231514, IND #40061) in the treatment of recurrent or persistent endometrial carcinoma: a phase II study of the Gynecologic Oncology.
David Miller (2009)
Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group.
D. Lorusso (2010)
35 – Tumors of the Lung, Pleura, and Mediastinum
K. Rosenzweig (2010)
Brief communication: use of the multitargeted antifolate pemetrexed (Alimta) in genitourinary cancer.
J. Misset (2002)
From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates
Jackie Walling (2006)
[Chemotherapy of malignant pleural mesothelioma: have we made any progress?].
M. Reck (2008)
What does a modified-Fibonacci dose-escalation actually correspond to?
N. Penel (2012)
Multitargeted antifolate (Pemetrexed): A comprehensive review of its mechanisms of action, recent results and future prospects
Delphine Exinger (2003)
Standard therapy for the treatment of malignant pleural mesothelioma.
N. Vogelzang (2005)
Pemetrexed disodium for the treatment of malignant pleural mesothelioma: a systematic review and economic evaluation.
Y. Dundar (2007)
Role of Pemetrexed in Non-Small Cell Lung Cancer
G. Longo-Sorbello (2007)
Pemetrexed disodium in combination with cisplatin versus other cytotoxic agents or supportive care for the treatment of malignant pleural mesothelioma.
J. Green (2007)
Efficacy and safety of first-line pemetrexed plus carboplatin followed by single-agent pemetrexed maintenance in elderly Chinese patients with non-squamous non-small-cell lung cancer
X. Zhao (2017)
See more
Semantic Scholar Logo Some data provided by SemanticScholar